B cells organize tumor-killing T cells in mouse breast cancer study

In a mouse model of triple-negative breast cancer, stimulating CD40 on B cells helped recruit cytotoxic CD8+ T cells into tumors, organize their distribution within the tumors and enhance their ability to kill cancer cells. The peer-reviewed study, led by Daniel Hollern’s laboratory at the Salk Institute and published in Cell Reports on September 10, 2026, provides experimental evidence for a role that had previously been associated with B-cell responses in people with cancer but remained mechanistically unclear. Its results identify B cells as regulators of antitumor immunity, while also showing that the findings were obtained in an animal model rather than a human clinical trial.

Current cancer immunotherapy often uses the body’s own immune system to fight tumors, with much of that work focused on T cells. Some T cells coordinate immune responses, whereas CD8+ T cells can eliminate infected and cancerous cells. Not every patient benefits from standard T-cell treatments, and the cellular mechanisms that determine whether tumor-killing T cells become effective remain incompletely understood.

B cells are best known for producing antibodies, but they have also been linked in cancer research to patient survival and responses to therapy. As senior author Hollern explained, “B cell responses have repeatedly been associated with better outcomes in people with cancer, but association alone cannot tell us what those cells are doing.” The new experiments address that gap by showing how B cells influence CD8+ T-cell behavior in mice. At the center of the investigation was CD40, a protein on the surface of immune cells including B cells, macrophages and dendritic cells.

CD40 interacts with CD40 ligand, a counterpart found primarily on T-cell surfaces. This signaling pathway is involved in immune responses, including those directed against cancer, and CD40-based approaches are being tested in clinical trials for triple-negative breast cancer, a difficult-to-treat form of breast cancer that lacks the three genetic markers targeted by many breast cancer drugs. “CD40 is becoming an important clinical target, so we wanted to understand what CD40 activation actually does to B cells in the context of cancer,” said Monika Quackenbush, a graduate student researcher in Hollern’s lab and co-first author of the paper.

The researchers therefore examined CD40 activation in a mouse model of triple-negative breast cancer. One principal finding was that treatment with a CD40 agonist produced a B-cell-dependent antitumor response in high-mutation-burden breast cancer models. The researchers interpreted the response as suggesting that B cells responded to many potential mutation-derived neoantigens, meaning abnormal proteins displayed on the surface of cancer cells.

The use of high-mutation-burden models is an important limitation: the experiment does not show that the same response will occur in breast cancers with fewer mutations, in other cancer types or in people receiving CD40 agonists. It demonstrates a mechanism under the conditions of the mouse models and identifies B cells as necessary for the antitumor effect observed there. The experiments also showed that B cells helped CD8+ T cells enter tumors and influenced how those cells were organized once inside.

This adds a spatial component to the immune response: B-cell activity was connected not only with the presence of tumor-killing T cells but also with their distribution within the tumor. The study therefore links CD40 stimulation and B-cell responses to both the movement of CD8+ T cells into breast cancer tumors and the arrangement they assume after entry. A third discovery was that B cells could directly signal CD8+ T cells to turn on their cytotoxic functions.

“Altogether, our results show that B cell responses to neoantigens and CD40 stimulation can facilitate CD8+ T cell tumoral responses, highlighting the influence B cells can have on CD8+ T cells,” said Kendrick Nguyen, a graduate student researcher in Hollern’s lab and co-first author. Taken together, the observations support a mechanistic sequence in which B cells participate in recruiting CD8+ T cells to tumors, influence their organization and enhance their tumor-killing activity. The findings connect antigen-associated B-cell responses, immune-cell positioning and T-cell cytotoxicity within one experimental antitumor response.

The paper, titled “B cell responses to CD40 stimulation ignite anti-tumor immunity by activating CD8+ T cell cytotoxicity,” moves beyond the observational relationships that have linked B-cell activity with clinical outcomes by testing specific cellular mechanisms. In the mouse system, CD40 stimulation was associated with a B-cell-dependent antitumor effect, while experiments involving B cells showed their influence on CD8+ T-cell recruitment, organization and cytotoxicity. That differs from a patient-level association between B-cell responses and outcomes, which by itself cannot identify what the cells are doing.

The results give B cells a possible therapeutic role that differs from their familiar antibody-producing function. Rather than acting only as factories for antibodies that identify and target pathogens or cancer cells, the study shows that B cells can help regulate the location and killing activity of CD8+ T cells in the mouse breast cancer model. “We’ve exposed that B cells can regulate CD8+ T cells to drive tumor cell killing,” Hollern said, “but we need to figure out how to optimize B cell function to unleash their full capacity to eliminate cancer.” The mechanism is attractive as a potential means of reinforcing immunotherapies that directly stimulate or engineer T cells, but that application remains a research goal.

The study did not establish a safe human dosing strategy, demonstrate clinical benefit or produce a combined treatment for patients. The work was conducted in mice with a model of triple-negative breast cancer, not in a prospective clinical trial. Hollern’s group plans to continue examining how B-cell function is regulated and how the newly identified interactions could be converted into therapeutic interventions.

“Our work really unearths new questions,” Hollern said. “We have made a lot of progress here, but ultimately there’s a lot more to explore—then we’ll have to connect the dots to harness these foundational biological insights in a therapeutic setting.” The study was supported by the National Institutes of Health, Metavivor, the Susan G. Komen Foundation, the California Breast Cancer Research Program, the Salk Institute Innovation Award, the Aileen S. Andrew Foundation, the Mary K. Chapman Foundation, Anderson Foundation, the Cancer Research Institute, the Henry L. Guenther Foundation, the Waitt Foundation, the Howard and Maryam Newman Family Foundation, the Helmsley Trust and other funders named by the institute. The central result is that, in mice, B cells did more than accompany the antitumor response: through CD40-linked activity, they helped direct where CD8+ T cells went, how they were arranged and how effectively they killed cancer cells.

Subject of Research: CD40-linked B-cell regulation of CD8+ T-cell antitumor activity in a mouse triple-negative breast cancer model

Article Title: Cancer biologists are bringing in the B cell reinforcements

Article References: Cancer biologists are bringing in the B cell reinforcements. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: B cells, CD40, CD8+ T cells, triple-negative breast cancer, mouse model, antitumor immunity, cancer immunotherapy, neoantigens, cytotoxic T cells, Salk Institute, Cancer, biologists